We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+0.54%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$414M
AUM Growth
-$36.3M
Cap. Flow
-$29.4M
Cap. Flow %
-7.11%
Top 10 Hldgs %
59.21%
Holding
41
New
5
Increased
13
Reduced
7
Closed
11

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$22.5M
2
BCYC
Bicycle Therapeutics
BCYC
+$16.4M
3
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$14.1M
4
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$11.9M
5
CYTK icon
Cytokinetics
CYTK
+$10.7M

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$49.3M
2
BCAB icon
BioAtla
BCAB
+$17M
3
MGNX icon
MacroGenics
MGNX
+$16.1M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$13.1M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$10.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.8%
2 Real Estate 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
1
Exelixis
EXEL
$13.3B
$29.5M 7.12%
1,300,000
-450,000
-26% -$8.79M
XENE icon
2
Xenon Pharmaceuticals
XENE
$6.06B
$28.1M 6.8%
920,000
-30,000
-3% -$898K
TVTX icon
3
Travere Therapeutics
TVTX
$5.2B
$26M 6.29%
1,010,000
+210,000
+26% +$5.58M
BCYC
4
Bicycle Therapeutics
BCYC
$269M
$24.2M 5.84%
550,592
+350,592
+175% +$16.4M
JAZZ icon
5
Jazz Pharmaceuticals
JAZZ
$15.9B
$24.1M 5.83%
+155,000
New +$22.5M
CYTK icon
6
Cytokinetics
CYTK
$10.5B
$23.9M 5.78%
650,000
+300,000
+86% +$10.7M
KDNY
7
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$23.3M 5.63%
1,423,682
+1,033,641
+265% +$14.1M
LKFT
8
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$22.3M 5.4%
360,000
+60,000
+20% +$3.67M
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$121B
$22.2M 5.36%
85,000
– –
PCVX icon
10
Vaxcyte
PCVX
$7.81B
$21.4M 5.17%
885,153
+385,153
+77% +$8.41M
RLMD icon
11
Relmada Therapeutics
RLMD
$557M
$21.3M 5.15%
790,000
+72,680
+10% +$1.5M
ANAB icon
12
AnaptysBio
ANAB
$1.58B
$17.3M 4.19%
700,000
+107,750
+18% +$3.26M
PNT
13
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$16.4M 3.97%
2,060,000
+1,869,480
+981% +$11.9M
ACRS icon
14
Aclaris Therapeutics
ACRS
$726M
$16.2M 3.93%
942,445
+142,445
+18% +$1.94M
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
$12.9M 3.11%
874,197
+462,260
+112% +$6.64M
RIGL icon
16
Rigel Pharmaceuticals
RIGL
$681M
$12M 2.89%
400,000
-100,000
-20% -$2.71M
KNSA icon
17
Kiniksa Pharmaceuticals
KNSA
$5.8B
$11.1M 2.69%
1,118,067
+581,329
+108% +$6.16M
TCDA
18
DELISTED
Tricida, Inc. Common Stock
TCDA
$10.3M 2.48%
1,250,000
-150,000
-11% -$1.36M
RNAM
19
DELISTED
Avidity Biosciences
RNAM
$9.23M 2.23%
500,000
– –
SLN
20
Silence Therapeutics
SLN
$495M
$8.44M 2.04%
444,443
– –
URGN icon
21
UroGen Pharma
URGN
$1.86B
$7.61M 1.84%
873,424
– –
PVLA
22
Palvella Therapeutics
PVLA
$1.99B
$6.66M 1.61%
27,488
+8,113
+42% +$2.13M
ARDX icon
23
Ardelyx
ARDX
$1.22B
$5.09M 1.23%
+4,761,905
New +$4.25M
VTYX
24
DELISTED
Ventyx Biosciences
VTYX
$4.56M 1.1%
+336,334
New +$4.49M
ABOS icon
25
Acumen Pharmaceuticals
ABOS
$155M
$3.63M 0.88%
+928,282
New +$5.05M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2022 Portfolio in Review

As of Q1 2022, Great Point Partners held 41 positions worth $414M, down 8.1% from $450M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Great Point Partners withdrew a net $29.4M in Q1 2022, closing 11 positions and reducing 7 holdings. Its most notable exit was Arena Pharmaceuticals Inc, an estimated $49.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Real Estate.

Against the trend, Great Point Partners opened a new position in Jazz Pharmaceuticals worth $24.1M.

  • Great Point Partners's largest Q1 2022 buy was Jazz Pharmaceuticals: 155,000 shares worth $24.1M.
  • Great Point Partners added most to Bicycle Therapeutics in Q1 2022, an estimated $16.4M increase.
  • Great Point Partners's biggest Q1 2022 reduction was Exelixis, cutting an estimated $8.79M.
  • Great Point Partners fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $49.3M.
  • Great Point Partners's ten largest holdings make up 59% of its $414M portfolio in Q1 2022.
  • Great Point Partners opened 5 new positions and closed 11 in Q1 2022.
  • Great Point Partners's portfolio value fell 8.1% quarter-over-quarter to $414M.

Based on Great Point Partners's 13F filing for Q1 2022, filed 16 May 2022.